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Introduction: CD4+CD25low/-GITR+ T lymphocytes expressing forkhead box protein P3 (FoxP3) and showing
regulatory activity have been recently described in healthy donors. The objective of the study was to evaluate the
proportion of CD4+CD25low/-GITR+ T lymphocytes within CD4+ T cells and compare their phenotypic and functional
profile with that of CD4+CD25highGITR− T lymphocytes in systemic lupus erythematosus (SLE) patients.
Methods: The percentage of CD4+CD25low/-GITR+ cells circulating in the peripheral blood (PB) of 32 patients with
SLE and 25 healthy controls was evaluated with flow cytometry. CD4+CD25low/-GITR+ cells were isolated with
magnetic separation, and their phenotype was compared with that of CD4+CD25highGITR− cells. Regulatory activity
of both cell subsets was tested in autologous and heterologous co-cultures after purification through a negative
sorting strategy.
Results: Results indicated that CD4+CD25low/-GITR+ cells are expanded in the PB of 50% of SLE patients. Expansion
was observed only in patients with inactive disease. Phenotypic analysis demonstrated that CD4+CD25low/-GITR+
cells display regulatory T-cell (Treg) markers, including FoxP3, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
transforming growth factor-beta (TGF-β), and interleukin (IL)-10. In contrast, CD4+CD25highGITR− cells appear to be
activated and express low levels of Treg markers. Functional experiments demonstrated that CD4+CD25low/-GITR+ cells
exert a higher inhibitory activity against both autologous and heterologous cells as compared with CD4+CD25highGITR−
cells. Suppression is independent of cell contact and is mediated by IL-10 and TGF-β.
Conclusions: Phenotypic and functional data demonstrate that in SLE patients, CD4+CD25low/-GITR+ cells are fully
active Treg cells, possibly representing peripheral Treg (pTreg) that are expanded in patients with inactive disease.
These data may suggest a key role of this T-cell subset in the modulation of the abnormal immune response in SLE.
Strategies aimed at expanding this Treg subset for therapeutic purpose deserve to be investigated.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by loss of tolerance to self-antigens,
which is followed by the activation and expansion of
autoreactive lymphocytes and the deposition of immune
complexes with an inflammatory/necrotic phenomenon in
different tissues.
Despite central mechanisms of tolerance, some T cells
recognizing self-antigens are released into the periphery,
and one of the mechanisms used to control these* Correspondence: carlo.riccardi@unipg.it
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stated.potentially damaging cells is the activity of regulatory T
cells (Tregs). Therefore, it has been suggested that auto-
immune diseases derive from the functional or numeric
imbalance between autoreactive T cells and Tregs [1-4].
Studies on patients with SLE found that effector T cells
are resistant to regulatory activity of Tregs [5,6]. In
addition, either reduced number or impaired function of
circulating Tregs in SLE has been also reported [7-11]. As
an apparent paradox, moreover, some studies described an
expansion of Tregs in autoimmune diseases, considered as
a homeostatic attempt to control activated effector T cells
[12-16]. Thus, conclusive data are still lacking [15,17].
Tregs were originally identified by high surface
expression of the CD25 molecule (CD25high), but further
studies indicated that only CD25high cells expressing theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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possess regulatory activity [18,19]. Moreover, regulatory
functions can be exerted also by CD4+CD25− cells [20,21],
and in SLE patients, CD4+CD25−FoxP3+ cells with a regu-
latory activity have been described [14,22].
Other proteins are differentially expressed in Tregs
and a number of different Treg subsets, characterized by
one or more markers, have been described [23-27]. Among
them, GITR is a marker overexpressed in murine CD4+
Tregs and with apparently contrasting functions. It favors
Treg expansion [28-31], but, in the short term, it inhibits
Treg activity by downregulating FoxP3 [32,33]. A problem
affecting most Treg markers is that they can be expressed
by cells devoid of regulatory activity, such as activated
effector cells. For example, the value of CD25 as a Treg
marker, particularly in tumor and autoimmune diseases, in-
cluding SLE, has been questioned after the demonstration
that CD25high cells are contaminated by activated effector
cells [8,34,35].
Because we recently demonstrated that CD4+CD25low/-
GITR+ T cells circulating in healthy subjects possess
regulatory activity and other features of Tregs, including
anergy [36], we were interested in analyzing number
and function of CD4+CD25low/-GITR+ T cells in SLE
patients in comparison with those of CD4+CD25high
GITR− cells.
We here demonstrate that CD4+CD25low/-GITR+ cells
are expanded in SLE patients, particularly in those with
inactive disease. Phenotypic and functional data demon-
strate that CD4+CD25low/-GITR+ cells are fully active
Tregs, whereas CD4+CD25highGITR− cells appear to be
contaminated by activated effector T cells. Taken together,
the present results point to a key role of CD4+CD25low/-
GITR+ cells in modulating the immune response in SLE.
Strategies focused on the expansion of this Treg subset
may offer new therapeutic approaches for SLE treatment.
Methods
Study population
Thirty-two patients with SLE, classified according to the
American College of Rheumatology criteria [37], were
enrolled, and 25 sex- and age-matched subjects acted as
healthy controls (HCs). Twenty-five of 32 patients were
women, mean age was 44 ± 11 years, and mean disease
duration was 9 ± 7 years. Clinical and serologic records
were collected at the time of enrollment, and disease
activity was measured by using the SLE disease activity
index (SLEDAI) [38]. Sixteen patients were taking hydroxy-
cloroquine, 200 mg/day, five patients were receiving myco-
phenolate mofetil, 2 g/day, and four patients were taking
azathioprine, 150 mg/day. Fifteen patients were also receiv-
ing less than 5 mg/day of prednisone. The whole study was
approved by the local ethics committee “Comitato Etico
delle Aziende Sanitarie Regione Umbria” (CEAS), andwritten informed consent was obtained in accordance with
the Declaration of Helsinki.Cell isolation
Peripheral blood (PB) mononuclear cells were isolated
from heparinized venous blood by gradient separation
(Ficoll-Hypaque), and CD4+ T cells were magnetically
sorted with negative immunoselection by using human
CD4+ isolation kit II and LD columns (Miltenyi Biotec).
Purity of CD4+ cells was >98.9%.
To perform real-time polymerase chain reaction (PCR),
cell subsets were isolated as previously reported [36]. For
CD62L evaluation, CD4+CD25−GITR− effector T cells
(1 × 106 cell/ml) were activated with PMA (50 ng/ml) and
ionomycin (250 ng/ml; Sigma-Aldrich) for 3 days.
To perform functional assays, CD4+ T cells were passed
through MACS columns after incubation with Biotin-anti
human CD25 and anti-Biotin microbeads. To avoid con-
taminating CD25+ cells, flow-through cells were passed
once again through MACS column (<1% of cells resulted
to be CD25+), thus obtaining CD25-depleted CD4+ T cells
(that include effector mixed with CD4+CD25low/-GITR+
cells) [39]. Half of flow-through was stained with PE-anti-
human-GITR and subsequently with anti-PE microbeads
to obtain CD4+CD25−GITR− effector cells in the flow-
through (cell purity >99%). GITR-depleted CD4+ cell
population (that include effector and CD4+CD25high
GITR− cells) was obtained similarly, by using anti-GITR
Ab instead of anti-CD25 Ab [39].Flow cytometry
To evaluate CD4+CD25low/-GITR+ cell percentage, CD4+
T cells were stained with PE-anti-human GITR (Biolegend),
Biotin-anti-human CD25 followed by anti-Biotin FITC
(Miltenyi Biotec), and their respective isotypes [36].
To perform a phenotypical characterization of CD4+
CD25low/-GITR+, cells were stained with the following
antibodies: PECy7-anti-human CD4 (BD Pharmingen),
AF647-anti-human CD25 (AbD Serotec), AF647-anti-
human GITR (Biolegend), FITC-anti-human CD45RO
(BD Pharmingen), FITC-anti-human CD45RA (BD Phar-
mingen), and FITC-anti-human CD127 (BD Pharmingen).
For intracellular FOXP3 staining, cells were perme-
abilized, fixed, and stained with anti-human FOXP3-AF647
(BD Pharmingen) by following the manufacturer’s instruc-
tions. To perform CTLA-4 staining, cells were cultured
with PMA, ionomycin, and monensin for 4 hours at 37°C,
permeabilized with saponin buffer, and incubated with
PE-anti-human CTLA-4 (BD Pharmingen) [36].
Samples were analyzed by using Beckman Coulter
EPICS XL-MCL flow cytometer running EXPO32 ADC
analysis software and BD Facscalibur running BD Cell-
Quest Pro analysis software.
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Total RNA was isolated with the RNeasy Mini extraction
kit (Qiagen), and RNA was reverse transcribed with
Quantitect reverse transcription kit (Qiagen). Real-time
PCR was performed in a Chromo 4 Four-Color Real-
Time System (Bio-Rad) using Taqman probes (Applied
Biosystems). The VIC-labeled housekeeping gene, hypo-
xanthine phosphoribosyl transferase 1 (HPRT)-1, was
amplified in the same tube of the FAM-labeled investi-
gated gene (four replicates). The ΔΔCt method was used
to determine expression of the gene of interest, and the
expression of effector cells were set equal to 1 [39].Functional assays
Effector T cells were stained with CFSE (Invitrogen, Life
Technologies); 2 μM) and co-cultured with unlabeled
effector, CD25-depleted or GITR-depleted CD4+ cells in
supplemented RPMI medium (0.25 × 105 and 0.75 × 105
cells/well, respectively; 5 × 105 cells/ml). Where indicated,
neutralizing anti-IL-10 (30 ng/ml; BD Pharmingen), anti-
TGF-β (0.5 μg/ml; R&D Systems) or isotype controls were
added.
Transwell experiments were performed in 24-well
Transwell plates with a 0.4 mm pore size (Corning).
TCR activation was obtained by coating the bottom and
the top chambers of the Transwell plates by cross-
linked goat anti-mouse mAb (Southern Biotech) and
mouse anti-human CD3ε [36]. CFSE-labeled effectors
were seeded in the bottom chamber of the 24-well plate
at a concentration of 0.5 × 105 cells/well. The unlabeled
cells (effectors, CD25-depleted or GITR-depleted CD4+
cells) were plated in the top chamber of the transwell at
1.5 × 105 cells/well.
CFSE dilution was evaluated after 4-day culture with
FACS analysis after TCR stimulation [36]. Regulatory
activity of CD4+CD25low/-GITR+ and CD4+CD25high
GITR− cells was calculated by comparing cell prolifera-
tion rate of effector cells co-cultured with effector cells
with that of effectors co-cultured with CD25-depleted
or GITR-depleted CD4+ cells, respectively, as previously
described [36].Statistical analysis
Mann Whitney U test was used to compare HC and SLE
patients. Kruskal-Wallis test with Dunn’s test for mul-
tiple comparison post hoc were used for the comparison
between HC, active SLE, and inactive SLE. Spearman
correlation coefficient, χ2 test, and binary logistic regres-
sion were also used, as detailed throughout the manu-
script. The significance level was two-sided and set at
P <0.05. All data analysis was performed by using IBM-
SPSS version 13.0.Results
CD4+CD25low/-GITR+ T cells are expanded in the PB of SLE
patients and particularly in those with inactive disease
The percentage of CD4+ Tregs characterized by GITR ex-
pression and low/negative levels of CD25 (CD4+CD25low/-
GITR+), recently described in HC [36], was evaluated in
SLE patients with flow cytometry (Figure 1A). As in HC
[36], the levels of expression of CD25 in this subset
(formally CD25−) were higher than those in CD25−GITR−
cells (effectors), as shown by both real-time PCR and flow
cytometry (Figure 1B,C). SLE patients with a percentage
of CD4+CD25low/-GITR+ cells higher than 1.4% (90th per-
centile of the distribution in HCs) were defined as having
an expansion of CD4+CD25low/-GITR+ cells (number 16;
50%). Consequently, the mean value of circulating CD4+
CD25low/-GITR+ Tregs in SLE was significantly higher
than detected in HCs (Figure 2A). This result was in
striking contrast with that observed in CD4+CD25high
GITR− and CD4+CD25highGITR+ Tregs, which were in
lower proportion and equal in SLE patients, respectively
(Figure 2B,C).
Taking into account the wide range of expansion of cir-
culating CD4+CD25low/-GITR+ cells in SLE, we wondered
whether they could be somehow related to general disease
activity. To this purpose, patients were divided into two
groups according to SLEDAI score: inactive disease pa-
tients with SLEDAI =0 (n =13) and active-disease patients
with SLEDAI >0 (n =19). As shown in Figure 2D, inactive
patients had a percentage of PB CD4+CD25low/-
GITR+ cells higher than those in active patients,
whereas the CD4+CD25highGITR− Treg percentage was
low, irrespective of disease activity (Figure 2E). Spear-
man correlation coefficient or binary logistic regression
was used to identify a possible relation between CD4+
CD25low/-GITR+ percentages and other clinical variables
such as age or therapy, but no significant difference was
observed.
Interestingly, an inverse correlation was found between
CD4+CD25low/-GITR+ and CD4+CD25highGITR− cell per-
centage (Figure 2F). In particular, 15 of 16 patients show-
ing a CD4+CD25highGITR− percentage <5% had a CD4+
CD25low/-GITR+ percentage higher than 1.4%, and 12 of
16 patients showing a CD4+CD25highGITR− percentage
higher than 5% had a CD4+CD25low/-GITR+ percentage
lower than 1.4% (Figure 2G).
CD4+CD25low/-GITR+ but not CD4+CD25highGITR− cells
show the same phenotype in SLE as in HC
Because circulating activated T cells are found in auto-
immune disorders, and CD25 and GITR are also markers
of activated effector T cells [27,40-42], we performed a
phenotypic characterization of CD4+CD25low/-GITR+ and
CD4+CD25highGITR− cells in SLE patients to verify whether
they showed a Treg or activated phenotype. The phenotype
Figure 1 Detection of circulating CD4+CD25low/-GITR+ cells in SLE patients. (A) Flow-cytometry analysis of anti-GITR and anti-CD25-stained
CD4+ T lymphocytes, freshly isolated from blood of a representative SLE patient, reveals the presence of a CD25−GITR+ cell subpopulation. Left
panel: gating strategy. Gated CD4+ T lymphocytes were stained with isotype control Abs (middle panel) or anti-GITR and anti-CD25 Abs (right
panel). (B) the levels of CD25 expression were evaluated in the upper left and lower left quadrants and MFI is reported. (C) mRNA expression of
CD25 (FAM6 fluorochrome) in the indicated subpopulations was evaluated in quadruplicate with real-time PCR. In the same tube, expression of
the housekeeping gene HPRT1 (VIC fluorochrome) was evaluated for normalization. Values of CD25 expression (striped column, CD25highGITR−;
black column, CD25low/-GITR+) is shown as fold increase of mRNA levels in the positively sorted subpopulations over mRNA levels in effector
(CD4+CD25−GITR−) T cells, arbitrarily set equal to 1. Data shown are mean ± SD of four SLE patients. ***P <0.001.
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CD4+ T cells (CD4+CD25−GITR−) and the respective cell
populations from HC.
CD62L expression is known to be high in naïve and
memory CD4+ effector cells and low in activated cells, and
CD4+CD25+CD62L+ but not CD4+CD25+CD62L− cells
have been found to possess regulatory activity [43,44].
Figure 3 shows that in HC, the mRNA levels of CD62L
were comparable in untreated naïve effector, CD4+
CD25low/-GITR+ and CD4+CD25highGITR− cells and
much lower (about ten fold) in PHA/ionophore-activated
effectors. In SLE patients, the mRNA levels of CD62L
were comparable in effector and CD4+CD25low/-GITR+
cells, suggesting that these cells were not activated
effector cells and possibly were Treg cells maintaining
regulatory activity. Conversely, CD4+CD25highGITR−
cells showed much lower levels of CD62L, thereby sug-
gesting that this subset includes activated effector T
cells or Treg cells devoid of regulatory activity.
We next evaluated the expression of the main Treg
markers. In CD4+CD25low/-GITR+ cells from SLE patients,
the mRNA expression of CTLA-4, IL-10, and TGF-β was
similar to those seen in CD4+CD25low/-GITR+ cells from
HC, and the mRNA expression of FoxP3 was even higher
(Figure 4A through D). At the protein level, the expressionof FoxP3 and CTLA-4 was similar to those seen in CD4+
CD25low/-GITR+ cells from HC [36], demonstrating that
CD4+CD25low/-GITR+ cells from SLE patients display a
Treg phenotype, as demonstrated in HC (Figure 4A, B).
Conversely, the level of FoxP3 mRNA in CD4+CD25high
GITR+ cells was lower than in CD4+CD25low/-GITR+ cells,
whereas the expression of FoxP3 protein was similar
(Figure 4A). Such a result is relevant because the expres-
sion of FoxP3 in HC is much higher in CD4+CD25high
GITR+ cells than in CD4+CD25low/-GITR+ cells [36]. The
expression of CTLA-4 was lower in CD4+CD25highGITR+
cells than in CD4+CD25low/-GITR+ cells at the mRNA
level while being similar at the protein level (Figure 4B).
Even in this case, such a result is relevant because the ex-
pression of CTLA-4 in HC is as much as threefold higher
in CD4+CD25highGITR+ cells than in CD4+CD25low/-GITR+
cells [36]. Moreover, TGF-β was not expressed in CD4+
CD25highGITR− cells from SLE patients.
Overall, our data suggest that most of the cells belong-
ing to CD4+CD25highGITR− subset and circulating in
SLE patients does not display a Treg phenotype.
The levels of CD45RO and CD45RA expression found
in CD4+CD25low/-GITR+ and CD4+CD25highGITR+ cells
(Figure 4E,F) suggest that the memory phenotype of
both subsets is more predominant in SLE patients than
Figure 2 Percentages of circulating CD4+CD25low/-GITR+ and CD4+CD25highGITR− cells in HC are different from those in SLE patients.
Percentage of CD4+CD25low/-GITR+ (A), CD4+CD25highGITR− (B) and CD4+CD25highGITR+ (C) in CD4+ T lymphocytes evaluated with flow-
cytometry analysis of anti-GITR- and anti-CD25-stained CD4+ T lymphocytes, isolated from PB of 25 HC and 32 SLE patients, is shown. Horizontal
lines indicate mean percentage. P values are according to Mann-Whitney U test comparing differences in HC and SLE. The percentage of patients
with more than 1.4% CD4+CD25low/-GITR+ cells (90th percentile of HC) is also indicated (A). Percentage of CD4+CD25low/-GITR+ (D) and
CD4+CD25highGITR− (E) in CD4+ T cells purified from freshly isolated PB of HC, patients with inactive disease identified by an SLEDAI =0 (n =13),
and patients with active disease identified by an SLEDAI >0 (n =19) was evaluated. Bars indicate mean ± SEM. n.s., P >0.05, *P <0.05 and
***P <0.001, according to Kruskal-Wallis test comparing active SLE, inactive SLE, and HC. (F) Correlation between levels of CD4+CD25low/-GITR+
and CD4+CD25highGITR− in CD4+ cells purified from freshly isolated SLE patients (Spearman ρ = −0.5; P <0.01). (G) Distribution of CD4+CD25high
GITR− cells according to the expansion of CD4+CD25low/-GITR+ cells. SLE patients with a percentage of these cells higher than 1.4% (90th
percentile of the distribution in HC) were defined as having expansion of the CD4+CD25low/-GITR+ cells (16 of 32 patients). P <0.001 according
to χ2 test on raw data.
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CD4+CD25low/-GITR+ cells (Figure 4G) were lower than
those observed in HC [36].
In SLE, CD4+CD25low/-GITR+ cells show a normal
regulatory activity, whereas CD4+CD25highGITR− cells
show a weak regulatory activity
Next, we verified the in vitro functional activity of CD4+
CD25low/-GITR+ and CD4+CD25highGITR− cells from
SLE patients. Because anti-GITR Ab must be used to
isolate GITR+ cells and GITR binding inactivates Treg
activity [29,36,45,46], isolated GITR+ cells cannot be
used to evaluate their regulatory activity. Therefore, we
adopted a previously described culture system in which
CFSE-labeled effectors (CD4+CD25−GITR−), obtained by
depletion of both CD25+ and GITR+ cells, are co-cultured
with CD25+ cell-depleted CD4+ cells, containing physio-
logical levels of CD4+CD25low/-GITR+ cells (CD25−GITR−
plus CD25low/-GITR+) [36,39,47]. To test their regulatory
activity, the proliferation of CFSE-labeled effectors co-
cultured with effectors and CFSE-labeled effectors co-cultured with “CD25−GITR− plus CD25low/-GITR+” cells
were compared. A similar approach was used to test the
regulatory activity of CD4+CD25highGITR− cells. In
particular, the proliferation of CFSE-labeled effectors
co-cultured with effectors and CFSE-labeled effectors
co-cultured with GITR+ cell-depleted CD4+ cells (CD25
−GITR− plus CD25highGITR−) were compared.
Our data demonstrated that CD4+CD25low/-GITR+ cells
from SLE patients exert regulatory activity on the prolifer-
ation of the respective autologous effectors at levels as
similar as those seen in HC (Figure 5A-C), confirming
that they are Tregs. Figure 5C shows that the mean regula-
tory activity by CD4+CD25low/-GITR+ cells from SLE pa-
tients was higher than that exerted by the same cells from
HC, but the difference was not significant. Not always did
CD4+CD25highGITR− cells from SLE patients exert a regu-
latory activity on the proliferation of the respective autolo-
gous effectors (Figure 5B), and their regulatory activity
was significantly lower than in HCs (Figure 5D), confirm-
ing functional differences between this subset in SLE
patients and HCs.
Figure 3 CD4+CD25low/-GITR+ cells from HC and SLE patients
express comparable levels of CD62L. CD62L mRNA expression
(fold decrease expressed in a base 2 logarithmic scale) in CD4+
CD25low/-GITR+ and CD4+CD25highGITR− T cells over the respective
naïve effector CD4+CD25−GITR− cell population, arbitrarily set
equal to 1. The levels of mRNA expression in effectors from HC and
SLE patients were similar. Expression level of CD62L mRNA in CD4
+CD25−GITR− effector cells activated by 72-hour treatment with PMA
plus ionomycin is also reported as control. Bars indicate mean ± SEM.
***P <0.001, according to Mann Whitney U test comparing expression
in Treg cell population (CD4+CD25low/-GITR+ and CD4+CD25highGITR−)
with that of the respective CD4+CD25−GITR− cell population. ###P
<0.001, according to Mann-Whitney U test comparing expression in
HC and SLE.
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GITR+ cells exert their regulatory activity, we performed
experiments by using transwells. Figures 5E-G shows
that the regulatory activity of CD4+CD25low/-GITR+ cells
is comparable with or without transwells, demonstrating
that the regulatory activity of CD4+CD25low/-GITR+ cells
is exerted without cell contact and suggesting that regu-
latory activity relies on soluble factors. Indeed, blocking
Abs directed against TGF-β and IL-10 inhibited the
regulatory activity of CD4+CD25low/-GITR+ cells partially
or completely, demonstrating that both cytokines medi-
ate the regulatory activity (Figure 6).
We next tested the effects of CD4+CD25low/-GITR+
and CD4+CD25highGITR− cells from SLE patients over
heterologous effectors from HC (Figure 7B). As control,
the effects of CD4+CD25low/-GITR+ and CD4+CD25high
GITR− cells from HC over heterologous effectors from
SLE patients were also tested (Figure 7A). In this heter-
ologous suppression assay, the regulatory activity exerted
by CD4+CD25low/-GITR+ cells from SLE patients resulted
higher than CD4+CD25highGITR− cells from SLE patients
as already demonstrated in autologous suppression tests
(Figure 5). Data deriving from all patients and HCs is
summarized in Figure 8.
Comparison between Figure 8D and C suggests that SLE
CD4+CD25low/-GITR+ cells over HC effectors had a much
higher regulatory activity than did HC CD4+CD25low/-
GITR+ cells over SLE effectors (P <0.01), and comparison
between Figure 8A and C suggests that HC CD4+CD25low/-GITR+ cells over HC effectors had a higher regulatory ac-
tivity than over SLE effectors, in accordance with the partial
resistance to suppression of SLE effectors [5,6]. Although
some studies suggest that the regulatory activity is more
active toward autologous effectors, the comparison between
Figure 8D and B suggests that SLE CD4+CD25low/-GITR+
cells had a slightly higher regulatory activity over HC effec-
tors than SLE effectors, again confirming the partial resist-
ance to suppression of SLE effectors. Nevertheless, SLE
CD4+CD25low/-GITR+ cells are more active than HC ones
in autologous suppression assay (Figure 8B and A).
We next compared the effect of CD4+CD25low/-GITR+
cells from HC and SLE patients on the same effector
cells from one HC. Figure 7C shows two representative
experiments of six. The mean inhibition by CD4+CD25low/-
GITR+ cells from HC was equal to 16.8% ±12.9% and the
mean inhibition by CD4+CD25low/-GITR+ cells from SLE
patients was equal to 27.2% ±14.5%, confirming that the
regulatory activity of cells from SLE was higher than that
from HC, when the inhibition of the same effectors was
evaluated.
To evaluate whether the higher regulatory activity of
CD4+CD25low/-GITR+ cells from SLE patients depended
on the number of CD4+CD25low/-GITR+ cells, we corre-
lated the percentage of CD4+CD25low/-GITR+ cells in
CD4+ cells from HC and SLE patients with the inhib-
ition of proliferation of effectors from the same subjects
by CD4+CD25low/-GITR+ cells (Figure 7D). Results show
that an apparent correlation between the high percent-
age of CD4+CD25low/-GITR+ cells in CD4+ in SLE pa-
tients and the high level of regulatory activity of CD4+
CD25low/-GITR+ cells from SLE patients is present.
However, correlation is not significant, possibly because
of the few data analyzed. Surprisingly, an inverse correl-
ation (nonsignificant) was observed in HC.
When comparing regulatory activity of CD4+CD25low/-
GITR+ and CD4+CD25highGITR− cells from HC, the
regulatory activity of CD4+CD25highGITR− was higher
than CD4+CD25low/-GITR+ in 18 of 19 assays (Figures 5A,
7A, and 8E). On the contrary, in SLE patients, the regula-
tory activity was always lower in CD4+CD25highGITR−
cells than in CD4+CD25low/-GITR+ cells (Figures 5B, 7B,
and 8E). The difference in the regulatory activity of the
two subsets in HC and SLE subject was highly significant,
confirming functional differences between SLE and HC
subsets, likely due to CD4+CD25highGITR− cells.
Discussion
It is recognized that the fine balance between Tregs and
effector T cells, regulating immune homeostasis, is often
disrupted in autoimmune disorders [1-4]. In particular,
some studies demonstrated a decreased activity of Treg
in SLE patients [8-11] and, in this setting, we investigated
whether the newly described CD4+CD25low/-GITR+ Treg
Figure 4 CD4+CD25low/-GITR+ cells from HC and SLE patients express comparable levels of Treg markers. Treg-marker mRNA expression
(fold increase expressed in a base 2 logarithmic scale) in CD4+CD25low/-GITR+ and CD4+CD25highGITR− T cells from HC and SLE patients over the
respective effector CD4+CD25−GITR− cell population arbitrarily set equal to 1 (A, B, left C, D). The levels of mRNA expression of genes in effectors
from HC and SLE patients were similar. Bars indicate mean ± SEM. *P <0.05; **P <0.01’ and ***P <0.001, according to Mann-Whitney U test
comparing expression in Treg cell population (CD4+CD25low/-GITR+ and CD4+CD25highGITR−) with the respective CD4+CD25−GITR− cell population.
#P <0.05; ##P <0.01; and ###P <0.001, according to Mann-Whitney U test comparing expression in HC and SLE. (A, B, middle and right) Expression
of FoxP3 (A) and CTLA-4 (B) in the indicated subpopulations was evaluated with flow cytometry. For CTLA-4 evaluation, cells were treated with
4 hours PMA plus ionomycin and monensin. Solid histogram represents isotype control. Results obtained with T cells from a representative
SLE patient are shown. (A, B right) MFI ratios (MFI of Ab-stained cells/MFI of isotype-stained cells) are mean ± SEM (bars) of three SLE patients.
*P >0.05, according to Mann-Whitney U test comparing expression in CD4+CD25low/-GITR+ cell population with that in CD4+CD25highGITR− cell
population. (E-G) Expression of CD45RO, CD45RA, and CD127 in the indicated subpopulations was evaluated with flow cytometry. Percentages
of positive cells are mean ± SEM (bars) of three SLE patients. *P <0.05, according to Mann-Whitney U test comparing expression in Treg cell
population (CD4+CD25low/-GITR+ and CD4+CD25highGITR−) with that of CD4+CD25−GITR− cell population.
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Figure 5 CD4+CD25low/-GITR+ but not CD4+CD25highGITR− cells from SLE patients exert a regulatory activity similar to HC. Regulatory
activity is independent of cell contact. CFSE-labeled effectors, activated with cross-linked anti-CD3 Ab, were co-cultured with autologous
unlabeled effectors (CD4+CD25−GITR−) (left, A, B), unlabeled CD25-depleted (including CD4+CD25−GITR− and CD4+CD25low/-GITR+)
(middle, A, B) or unlabeled GITR-depleted (including CD4+CD25−GITR− and CD4+CD25highGITR−) cells (right, A, B) at 1:3 cell ratio.
Proliferation was evaluated after 4 days with flow cytometry. Graphs show inhibition of proliferation by CD4+CD25low/-GITR+ and CD4+CD25high
GITR− (histograms A, B) and the differences between the inhibition (plot on the right) in each subject (A, B). Experiments with
cells from PBs of two representative HCs (A) and two representative SLE patients (B) are shown. (C, D) Histograms show mean percentage of
inhibition of proliferation by CD4+CD25low/-GITR+ (C) and CD4+CD25highGITR− (D) cells from twelve HCs and six SLE patients. (E, F) Inhibition by
CD4+CD25low/-GITR+ and CD4+CD25highGITR− in an identical experiment as the described (classical) and in transwell experiments (unlabeled cells
above and CFSE-labeled cells below the transwell). A representative SLE patient of 3 is shown. Graph in G shows differences in the inhibition of
proliferation by CD4+CD25low/-GITR+ in the classic and transwell experiments in the three patients. ***P <0.001 according to Mann-Whitney U test,
comparing inhibition by CD4+CD25highGITR− cells from HC and SLE patients.
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CD25low/-GITR+ cells display all the properties of Tregs.
Interestingly, the mean regulatory activity of CD4+
CD25low/-GITR+ cells was higher in SLE patients
(though not significantly different) than in HCs. Taking
into account that CD4+CD25low/-GITR+ cells in SLE are
in greater number than in HCs, even their regulatory
activity may appear stronger, accordingly (see Figure 7D).
Therefore, the levels of regulatory activity of CD4+Figure 6 Blocking TGF-β and IL-10 inhibits the regulatory activity of C
effectors, activated with cross-linked anti-CD3 Ab, were co-cultured with au
CD25-depleted (including CD4+CD25−GITR− and CD4+CD25low/-GITR+) (righ
and, in panel C, blocking anti-IL-10 Ab (30 ng/ml) were added. Proliferation
left show inhibition of proliferation by CD4+CD25low/-GITR+ in the presence
is shown. Histograms on the right show the mean inhibitory effect of bloc
of CD4+CD25low/-GITR+ cells, observed in cells from three SLE patients ± SECD25low/-GITR+ cell on a cellular basis may be higher,
equal to, or even lower in SLE patients than in HCs. The
levels of expression of Treg markers in CD4+CD25low/-
GITR+ cells were equal or significantly greater in SLE pa-
tients than in HCs, suggesting that CD4+CD25low/-GITR+
cells represent activated Tregs [48,49]. The hypothesis is
in line with the possibility that effector T cells are partly
activated in autoimmune diseases [5,6], thus eliciting Treg
activation. In summary, our data overall demonstrate thatD4+CD25low/-GITR+ cells from SLE patients. (A-C) CFSE-labeled
tologous unlabeled effectors (CD4+CD25−GITR−) (left) or unlabeled
t) at a 1:3 cell ratio. In panel B, blocking anti-TGF-β Ab (0.5 μg/ml)
was evaluated after 4 days with flow cytometry. Histograms on the
(B, C) or absence (A) of blocking Abs. One representative SLE patient
king anti-TGF-β Ab (B) and anti-IL-10 Ab (C) on the regulatory activity
M (bars). **P <0.01 according to the Mann-Whitney U test.
Figure 7 (See legend on next page.)
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Figure 7 In SLE patients, the regulatory activity exerted by CD4+CD25low/-GITR+ cells is higher than CD4+CD25highGITR− cells. CFSE-
labeled effector T cells from SLE (A) or HC (B) patients, activated with cross-linked anti-CD3 Ab, were co-cultured with heterologous unlabeled
effector (CD4+CD25−GITR−) (left, A and B), heterologous unlabeled CD25-depleted (including CD4+CD25−GITR− and CD4+CD25low/-GITR+) (middle,
A and B) or heterologous unlabeled GITR-depleted (including CD4+CD25−GITR− and CD4+CD25highGITR−) cells (right, A and B) at a 1:3 cell ratio
from HC (A) or SLE patients (B). Proliferation was evaluated after 4 days with flow cytometry. Experiments with cells from two representative SLE
patients co-cultured with cells from two representative HCs are shown. Graphs show inhibition of proliferation by CD4+CD25low/-GITR+ and CD4+
CD25highGITR− (histograms) and the differences between the inhibition (plots) in each subject (A, B). (C) CFSE-labeled effector T cells from HC, acti-
vated with cross-linked anti-CD3 Ab, were co-cultured with HC (left) or SLE (middle right) unlabeled effector (CD4+CD25−GITR−) or HC (middle left)
or SLE (right) unlabeled CD25-depleted (including CD4+CD25−GITR− and CD4+CD25low/-GITR+) cells at a 1:3 cell ratio. Histogram show inhibition of
proliferation of labeled HC effector by HC and SLE CD4+CD25low/-GITR+ cells. (D) Correlation between levels of CD4+CD25low/-GITR+ in CD4+ cells
purified from HC and SLE patients and inhibition of proliferation by CD4+CD25low/-GITR+ cells from the same subjects (CD4+CD25low/-GITR+ cells from
SLE patients; Spearman ρ =0.77, P =0.10; CD4+CD25low/-GITR+ cells from HC, Spearman ρ = −0.71, P =0.13).
Figure 8 Regulatory activity of CD4+CD25low/-GITR+ and CD4+CD25highGITR− cells from HC differs from that of SLE patients. Inhibition of
proliferation by CD4+CD25low/-GITR+ cells and CD4+CD25highGITR− cells observed in autologous (see Figure 5) and heterologous (see Figure 7)
co-cultures is shown (A-D). **P <0.01 and ***P <0.001 according to Mann-Whitney U test comparing inhibition by CD4+CD25low/-GITR+ cells and
CD4+CD25highGITR− cells. (E) Differences between regulatory activity exerted by CD4+CD25highGITR− and CD4+CD25low/-GITR+ Treg from each HC
(circle) and SLE patient (triangle) is reported, as shown in right plots of Figures 5 and 7. Horizontal lines indicate mean differences. ***P <0.001,
according to the Mann-Whitney U test comparing differences in HC and SLE.
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Treg phenotype (possibly those of activated Treg) and
exert a clear regulatory activity at levels similar to those of
HC cells.
After their discovery, CD4+CD25low/-GITR+ subset in
HCs were referred to as CD25low, despite formally being
CD25−, as assessed by flow cytometry. CD25low means
that their CD25 expression level was higher than in
effector cells, as shown by both real-time PCR and flow
cytometry [36]. These data were confirmed also in cells
from SLE patients, as shown in Figure 1. Moreover,
these cells, now referred to as CD4+CD25low/-GITR+, are
FoxP3+ and CTLA-4+, suggesting that in SLE disease
they continue to show a regulatory phenotype. In fact,
our results confirm an active role of CD4+CD25low/-
GITR+ in T-cell suppression because, as observed in
HCs, SLE CD4+CD25low/-GITR+ cells produce high
amounts of TGF-β and IL-10 and their neutralization,
by blocking Abs, inhibits their suppressive activity. Our
previous study did not report a role of IL-10 in
mediating CD4+CD25low/-GITR+ suppressive activity
[36], probably as a consequence of the use of anti-IL-10
neutralizing Ab not tested for functional assays.
We also demonstrated that CD4+CD25low/-GITR+ cells
are expanded in SLE patients and show a predominant
memory phenotype. Results from our and previous
studies strongly suggest that CD4+CD25low/-GITR+
cells are more likely pTregs, such as Tr1, rather than
thymic Treg (tTreg). Indeed, they are expanded
memory cells and do not suppress effector cells by cell
contact but only by production of immunomodulatory
cytokines.
Expansion of CD4+CD25low/-GITR+ recalls three re-
cent studies describing the expansion of CD4+CD25−
FoxP3+ cell subset in SLE patients [14,22,50]. Because
CD4+CD25−FoxP3+ cell subpopulation includes CD4+
CD25low/-GITR+ cells, we can suppose that the de-
scribed expansion of the CD4+CD25−FoxP3+ cell subset
is due, at least in part, to the expansion of CD4+CD25low/-
GITR+ cells. Notably, Bonelli et al. and this study demon-
strate that these subsets have regulatory activity [14],
whereas Zhang et al. [22] do not confirm these findings.
As suggested by Horwitz [51], these differences may
depend on the evaluated patient. Indeed, Zhang et al.
studied untreated new-onset SLE patients whereas
Bonelli et al. and we studied patients with long-
standing disease.
The idea that autoimmune diseases derive from func-
tional or numeric imbalance between autoreactive T cells
and Tregs is well established. It has been demonstrated
that the CD4+CD25high cells are less active and/or less
frequent in SLE patients [7-11], as confirmed by the
present study. Nevertheless, Tregs contribute, at least in
part, to the control of the disease, as demonstrated byunmasking autoreactive CD4+ T cells with the removal
of Tregs [52]. In this setting, it has been hypothesized
that subsets of Tregs may arise under specific auto-
immune conditions as an effort to counteract the activity
of effectors leading to autoimmunity [15]. This hypoth-
esis seems to be confirmed by recent studies describing
the expansion of Treg subsets in SLE [12,14,16,50].
Interestingly, we observed an expansion of circulating
CD4+CD25low/-GITR+ Treg cells and a correlation be-
tween their number and inactive disease, suggesting that
expansion of CD4+CD25low/-GITR+ cells is a homeostatic
event to control the disease. The findings we recently
described in patients with primary Sjӧgren syndrome ap-
pears to support this hypothesis [39]. In this context, the
results of recent studies showing Treg subset expansion in
SLE patients with active disease are only apparently in
contrast with our data. The expansion of CD4+CD25−
FoxP3+ cells found by Bonelli et al. [14] in active SLE was
associated with defective Treg function of these cells,
thereby suggesting a possible contamination with non-
Treg cells [14]. Similarly, the Treg cells identified as
CD45RA+FoxP3low by Pan et al. [13] were expanded in
active SLE but with a defective suppressive activity [13].
Finally, the in vitro evaluation of regulatory activity of
FoxP3+Helios+ Treg cells, increased in SLE and positively
correlated to disease activity, was not feasible for technical
problems [16].
When transferring the concept of Tregs from rodents
to humans, an important issue was the inability to easily
identify human functional Tregs in patients with various
autoimmune diseases. For example, it is known that only
a subset of T cells identified as CD4+CD25high by flow
cytometry are functionally suppressive Tregs, whereas
others are activated effector T cells [35,53]. In SLE
patients, the contamination of CD25high subset with a
more activated/autoreactive cells is confirmed by both
phenotypic and functional studies. In fact, CD25high cells
expressing FoxP3 are in a lower percentage than in HCs
[34]. Moreover, CD25high cells display an activated pheno-
type [5,10] and have a decreased regulatory activity [8-10].
Our study confirms that the regulatory potential of
CD4+CD25highGITR− cells (the most represented among
CD25high cells [36]) is weaker in SLE patients than in HCs
and that CD4+CD25highGITR− cells, expressing low levels
of Treg markers, are activated cells. Conversely, CD4+
CD25low/-GITR+ cells maintain all the phenotypic and
functional features of Treg cells. Interestingly, in patients
where the percentage of CD4+CD25low/-GITR+ cells is
high, the percentage of CD4+CD25highGITR− cells is low
and vice versa (Figure 1F). If we consider the majority of
CD4+CD25highGITR− cells as activated effector cells, the
inverse correlation may suggest that CD4+CD25low/-
GITR+ cells counter expansion of autoreactive/activated
cells, as also confirmed by the clinical correlation
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activity.
It has been hypothesized that an increased number of
fully active Tregs could revert the imbalance of suppres-
sor/effector cell ratio and may change the natural history
of autoimmune diseases. Indeed, therapies that increase
Treg numbers and activity have been shown to be effect-
ive at reversing autoimmune diseases in animal models
such as experimental autoimmune encephalitis [54] and
diabetes [55]. Of note, ex vivo expanded regulatory T
cells, adoptively transferred in lupus-prone mice, reduced
the rate of renal disease development, and a second trans-
fer, in animals that already developed proteinuria, further
delayed the progression of renal disease and significantly
improved survival [56]. Moreover, a single transfer of TGF-
β-conditioned T cells to animals decreased circulating anti-
dsDNA Abs, reduced proteinuria, and doubled survival
[57]. A phase I/II trial using Tr1 cell clones in patients dis-
playing severe Crohn disease, yielded encouraging results
[58] and a dose-escalation trial using autologous ex vivo
expanded polyclonal Tregs (CD4+CD25+CD127-/lo) in dia-
betes patients is currently ongoing [59].
We believe that in vitro expanded autologous/
heterologous Tregs may help treat autoimmune diseases,
including SLE, and that CD4+CD25low/-GITR+ cells are
interesting from this point of view, because they appear
to be a homeostatic attempt to counteract the disease.
Protocols to expand CD4+CD25low/-GITR+ cells are
under study and may include TCR/GITR co-triggering
or TCR/CD28 co-triggering in the presence of immuno-
suppressive drugs.Conclusions
In conclusion, the present data, together with those pre-
viously published on patients with primary Sjӧgren syn-
drome [39], suggest that CD4+CD25low/-GITR+ cells are
expanded pTregs in response to an effector/Treg imbal-
ance and are able to control, at least in part, the disease.
In SLE patients, the CD4+CD25low/-GITR+ subset does
not appear to be contaminated by activated cells devoid
of regulatory activity, suggesting that GITR could be used
as valuable surface marker of Tregs. Strategies aimed to
expand the CD4+CD25low/-GITR+ subset for therapeutic
purposes deserve to be investigated.Abbreviations
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